Biomarin Pharmaceutical (BMRN) Retained Earnings (2009 - 2026)

Biomarin Pharmaceutical has disclosed Retained Earnings across 18 years of filings, most recently posting $259.7 million for Q1 2026.

• Quarterly Retained Earnings rose 1256.24% year-over-year to $259.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259.7 million (up 1256.24% YoY) and the FY2025 annual result came in at $154.2 million, up 179.2% from the prior year.
• Retained Earnings rose to $259.7 million in Q1 2026, from $154.2 million in the prior quarter.
• Over five years, Retained Earnings peaked at $259.7 million in Q1 2026 and troughed at -$789.2 million in Q4 2022.
• A 5-year average of -$199.5 million and a median of -$28.8 million in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings tumbled 84090.08% — and 2025, when it soared 4217.83%.
• Tracing BMRN's Retained Earnings over 5 years: stood at -$789.2 million in 2022, then surged by 96.35% to -$28.8 million in 2023, then slumped by 576.31% to -$194.7 million in 2024, then surged by 179.2% to $154.2 million in 2025, then soared by 68.43% to $259.7 million in 2026.
• Business Quant data shows BMRN's Retained Earnings at $259.7 million in Q1 2026, $154.2 million in Q4 2025, and $200.8 million in Q3 2025.